Last year was rather rough for Xoma Corp. In March 2011, the company saw its interleukin-1 beta inhibitor gevokizumab miss its primary endpoint in a Phase IIb trial in Type II diabetes, eliminating the opportunity to enter the lucrative market. (See BioWorld Today, March 24, 2011.) Read More
Triple-negative breast cancer (TNBC) is named for what it does not have. This subtype of breast cancer does not express estrogen receptors, the progesterone receptor, or HER2/neu. That classification, though, doesn't give doctors any clues as to what might actually work to fight it – only what won't. Read More
